ESMO 2023 | Predictors of HRQOL in espohageal cancer post-nCRT and esophagectomy

Berend J. Van der Wilk, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, provides an overview of research regarding the effect of neoadjuvant chemoradiotherapy (nCRT) and surgery on health-related quality of life (HRQOL) in patients with espohageal cancer. Patients with locally advanced esophageal cancer, who are in a favorable condition at the beginning, were found to experience greater declines in various HRQOL outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.